Skip to content
sellWeak10b5-1 plan

Chris Francis sold $500k of WVE

See Remarks at Wave Life Sciences Ltd.. 33,194 shares at an average of $15.05, traded Feb 26, 2026, filed Feb 27, 2026.

Warning score
8
Value
$500k
33,194 shares
Holdings after
61,867
-42% from before
From 52-week low
+180%
low $5.48, close $15.36
From 52-week high
-28%
high $21.31, as of Feb 26, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $500k at market
    +18
  • Share of holdings sold
    Sold 42% of holdings
    +10
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -54.3%, 3m -52.8%, 6m -63.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

WVEOct 13, 2026 · close 3.14
Since filing Feb 27, 2026: -77.5%SPY +14.3% · excess -91.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-083712, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 26, 2026MOption exercise
Ordinary Shares10b5-1
+17,900$3.87$69k79,767Feb 27, 2026
Feb 26, 2026SOpen-market sale
Ordinary Shares10b5-1
-17,900$15.09$270k61,867Feb 27, 2026
Feb 26, 2026MOption exercise
Ordinary Shares10b5-1
+15,294$4.75$73k77,161Feb 27, 2026
Feb 26, 2026SOpen-market sale
Ordinary Shares10b5-1
-15,294$15.00$229k61,867Feb 27, 2026
Feb 26, 2026MOption exercise
Share Option (right to buy)derivative10b5-1
-17,900$0.00$0143,200Feb 27, 2026
Feb 26, 2026MOption exercise
Share Option (right to buy)derivative10b5-1
-15,294$0.00$061,175Feb 27, 2026

Related signals

Other insiders at Wave Life Sciences Ltd. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
38Weak
WVEsell 410b5-1
Wave Life Sciences Ltd.
Adrian Rawcliffe
director
$67k
12,700 shares
-100%
15Weak
WVEsell 410b5-1
Wave Life Sciences Ltd.
Ken Takanashi
director
$23k
3,864 shares
-16%
10Weak
WVEsell 410b5-1
Wave Life Sciences Ltd.
Aik Na Tan
director
$2,596
432 shares
-2%
6Weak
WVEsell 410b5-1
Wave Life Sciences Ltd.
Heidi L Wagner
director
$42k
7,000 shares
-13%
49Moderate
WVEbuy
Wave Life Sciences Ltd.
Ra Capital Management, L.p.
director, owner
$55M
8,772,496 shares
+48%
51Moderate
WVEsell 4
Wave Life Sciences Ltd.
Paul Bolno
President and CEO
$141k
10,480 shares
-4%
35Weak
WVEsell 4
Wave Life Sciences Ltd.
Chris Francis
See Remarks
$25k
1,883 shares
-3%
44Moderate
WVEsell 4
Wave Life Sciences Ltd.
Kyle Moran
Chief Financial Officer
$48k
3,588 shares
-3%
36Weak
WVEsell 4
Wave Life Sciences Ltd.
Chandra Vargeese
See Remarks
$43k
3,228 shares
-1%
1Weak
WVEsell10b5-1
Wave Life Sciences Ltd.
Chris Francis
See Remarks
$150k
9,375 shares
-27%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Chris Francis sold $500k of WVE | InsiderTell